Industry Profile

Biodefense and Biosecurity Research

Target researchers — Infectious disease scientists, biosafety researchers, public health microbiologists, vaccine developers, and government laboratory scientists working on select agents and emerging biothreats.

Biodefense and biosecurity research develops scientific capabilities—vaccines, therapeutics, diagnostics, and surveillance systems—to protect civilian and military populations from biological threats whether natural outbreaks, accidental releases, or deliberate bioterrorism attacks. BARDA, NIH NIAID, and the DoD fund a substantial portion of the sector through companies such as Emergent BioSolutions, SIGA Technologies, Bavarian Nordic, and Inovio Pharmaceuticals. Scientists procure BSL-3 and BSL-4 containment equipment—biosafety cabinets, high-efficiency HEPA systems, glove boxes, pressure-controlled suites—alongside rapid diagnostic PCR platforms, aerosol challenge chambers, non-human primate study management tools, and secure genomic databases for pathogen characterization. The COVID-19 pandemic revitalized public investment in medical countermeasure readiness, with new funding streams for mRNA-based biothreat vaccines and pan-coronavirus broadly neutralizing antibodies. Sell to Scientists CLI serves research programs needing compliant sourcing for select-agent reagents, certified PPE, and specialized laboratory infrastructure.

Key Companies